New Project Puts Standardized Outcomes Measures for Depression into Real-World Use, from Registries to the Clinic OM1 partners with AHRQ, ABFM, APA and others to implement BOSTON, July 17, 2019 —OM1, a leading health outcomes and technology company, today announced it is has been awarded the CAPSTONE – Outcome Measure Harmonization and Data Infrastructure for[…]
OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to[…]
March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]
Published on HealthEconomics.com on January 3, 2018 As artificial intelligence (AI) and Big Data are lauded for their potential uses in life sciences and healthcare, it is becoming difficult to differentiate between the myriad of terms and technologies and their real value in advancing real-world evidence (RWE). In this article, we explore key AI[…]
January 30, 2018 – 11 am – 12 pm ET – Register Fibrotic diseases, such as non-alcoholic steatohepatitis (NASH), are responsible for 45% of US deaths a year. With a growing occurrence and few treatment options, more research is needed to better understand natural history and progression of these diseases, treatments and outcomes. This session[…]
